All Activity

Delight in the highest satisfaction with our meticulously selected array of Kanpur's independent and agency-affiliated escorts, all of whom excel in delivering unparalleled gratification. Each partner offers a distinctive method for fulfilling your deepest desires, ensuring that every encounter is fresh, thrilling, and memorable. Escort Service Kanpur || Escort Service in Kanpur || Kanpur Escort || Escort in Kanpur || Kanpur Escort Service

Along with their talent and versatility, our escorts have extensive experience with us and possess a high level of education and sophistication. We understand that affluent and prosperous gentlemen seek a reliable Lucknow Escort Service to effortlessly and discreetly fulfill their desires. So, why delay? Contact us today to secure your enchanting perfect match.

Also creates an enjoyable rhythm that keeps stickman hook players mentally engaged. Each level follows a natural flow, where successful swings lead smoothly into the next challenge. This rhythm helps players develop a sense of anticipation and timing, which enhances immersion. Over time, players begin to move instinctively, reacting to hooks and obstacles almost automatically. This sense of rhythm is a hallmark of well-designed physics-based games.

Marijuana has therapeutic benefits for adults with disabilities and is commonly utilized to manage pain and other symptoms, a new government-funded study shows. “Cannabis use is prevalent across disability domains and the majority of respondents note they use cannabis to help with pain and to relax or relieve tension,” the researchers wrote. More than one in five people surveyed said they currently use cannabis—and the most commonly reported reason was relief of pain, at over 70 percent. More than 60 percent said marijuana helps to relax or relieve tension. “Specific medical reasons for using cannabis included assistance with health-related conditions such as migraines, nausea, muscle spasms, seizures, mental health concerns, and sleep disturbances,” the researchers wrote. The data and results were derived from the National Survey on Health and Disability, an annual measure of nearly 2,000 people who self-identify as living with a disability. The authors, affiliated with George Mason University and the University of Nevada, noted the methodology took into account participants’ self-reported limitations, including disabilities related to cognition, hearing, independent living, mobility, self-care and vision. The study was published in the November 2025 issue of the Disability and Health Journal. The researchers issued a note of caution regarding the study’s potential limitations, emphasizing that data were self-reported. “The cannabis use reason question does not ask specifically why respondents are currently using cannabis, and therefore respondents may have endorsed reasons for cannabis use in the past,” they wrote, adding that “the sample is not a representative sample and is majority white, female, college-educated, and affluent; therefore, the generalizability of these results to other demographics is unknown.” The study was funded by a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research, an agency within the National Institutes of Health. “We found that approximately one fifth of adults with disabilities had reported using cannabis currently.” Beyond cannabis’s direct effect in easing the symptoms of people with disabilities, legalization is helping in other ways. In recent years, for example, Colorado officials have prioritized funding programs for disabled communities with revenue generated by cannabis sales—most recently with an auction for marijuana-themed license plates. The post Medical Marijuana Use Is ‘Prevalent’ Among People With Disabilities—And It Helps Treat Pain, New Federally Funded Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A bipartisan majority of Americans support federally rescheduling marijuana, according to a new poll. And most also believe it should be entirely legal for adults to use cannabis. The YouGov survey was released just days after President Donald Trump directed the attorney general to expeditiously complete the process of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). The reform wouldn’t legalize cannabis, but it would symbolically recognize the plant’s medical value, while allowing marijuana businesses to take federal tax deductions and remove certain research barriers associated with Schedule I drugs. According to the poll, Americans are on board with the policy change. Here’s how the question was framed: “Do you approve or disapprove of the government reclassifying marijuana from the most restrictive category of drugs to a less restrictive category that allows for research on its potential medicinal uses?” Overall, 70 percent of respondents said they either “strongly” (42 percent) or “somewhat” (28 percent) approve of rescheduling. Just 16 percent said they oppose the reform, while 14 percent said they were unsure. Dec 19-22 poll of 31,080 U.S. adults (+/-0.8 point) % who approve | disapprove of the government reclassifying marijuana to a less restrictive category of drugs U.S. adults 70% | 16% Democrats 78% | 11% Independents 69% | 14% Republicans 66% | 21% (Link in reply) pic.twitter.com/tX36YE8xAZ — YouGov America (@YouGovAmerica) December 22, 2025 Notably, support crossed party lines, with 78 percent of Democrats, 69 percent of independents and 66 percent of Republicans in favor of reclassifying cannabis. The majority support is consistent with earlier polling, including one survey released earlier this year from a firm with ties to the president. YouGov also asked about the potential broader legalization of marijuana possession by adults, and a smaller majority (54 percent) said that should be permitted, including 68 percent of Democrats and 55 percent of independents. Republicans were evenly split on the question, with 41 percent in favor and 41 percent opposed. Separately, a majority of respondents (76 percent) also said marijuana either “definitely” (43 percent) or “probably” (33 percent) has “legitimate medical uses.” On that question, there was also bipartisan agreement. Democrats were most likely to say cannabis has medical value (84 percent), followed by independents (74 percent) and Republicans (73 percent). % who think that marijuana definitely or probably does | doesn't have legitimate medical uses U.S. adults 76% | 13% Democrats 84% | 9% Independents 74% | 12% Republicans 73% | 17%https://t.co/QeMPF23OF9 pic.twitter.com/zT2bNPqNHE — YouGov America (@YouGovAmerica) December 22, 2025 The survey involved interview with 31,080 U.S. adults from December 19-22, with a +/-0.8 percentage point margin of error. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The rescheduling process initiated by the Biden administration, which Trump has now asked to be finalized, is still pending. But as prior polling has indicated—and this latest survey has reinforced—it’s a politically popular reform across the aisle. The president said last week that cannabis can “make people feel much better” and serve as a “substitute for addictive and potentially lethal opioid painkillers.” He clarified, however, that he personally has no interest in using marijuana himself. Trump also dismissed the concerns of GOP lawmakers who oppose rescheduling, pointing out that an overwhelming majority of Americans support the reform and that cannabis can help people—including his personal friends—who are suffering from serious health issues. Photo courtesy of Brian Shamblen. The post Bipartisan Majority Of Americans Support Rescheduling Marijuana And Say It Has Medical Value, New Poll Finds After Trump Takes Action appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Szukasz wiarygodnych informacji przed wyborem kasyna online?Znajdziesz tu rzetelne recenzje, aktualne rankingi oraz sprawdzone bonusy dla polskich graczy.Sprawdź kasyno online opinie https://legalne-kasyno.online/ i wybierz bezpieczną platformę do gry.

EU5 takes players to the most challenges.Your ultimate resource for Europa Universalis V mastery. Expert guides, professional reviews, and community insights all in one place.

“Our marijuana laws are stuck in the dark ages–overly punitive, out of step with our neighbors and holding our state back.” By Sam Stockard, Tennessee Lookout Tennessee lawmakers on both sides of the aisle are calling for new marijuana laws following President Donald Trump’s executive order to loosen cannabis restrictions. Democratic Sen. London Lamar of Memphis and Republican Rep. Jeremy Faison of Cosby in East Tennessee both said they believe the state needs reform after the president ordered the reclassification of marijuana to Schedule III from Schedule I on the Federal Drug Administration’s list of controlled substances, an indication it has medicinal value but still could be abused. Tennessee is one of 10 states that restricts medicinal and recreational marijuana while 22 other states have legalized some form of recreational use. Democratic Sen. London Lamar of Memphis said Tennessee lawmakers should take note of the federal move and pass new laws for medical use, decriminalization or legalization. “Our marijuana laws are stuck in the dark ages–overly punitive, out of step with our neighbors and holding our state back,” Lamar, chairman of the Senate Democratic Caucus, said in a statement. The state should support medical research of cannabis for treatment of patients who would choose it for pain medication over dangerous opioids, she said. Lamar added that the state also should stop wasting money incarcerating people for marijuana violations and divert those funds to roads, schools and healthcare. Faison, who previously pushed passage of medical marijuana laws, said the federal government never had a “sound justification for a naturally occurring plant” to be classified as a Schedule I drug. That made it comparable to heroin, LSD and Ecstasy. Nor did the federal government have a “solid basis to dictate” cannabis regulations to states, Faison said, adding the change brings a “safer, more practical” approach. “I truly hope that this fosters medical research that either debunks what many sick Americans have testified to or provides the evidence and foundation showing that cannabis is safer than opioids and other man-altered substances,” said Faison, chairman of the House Republican Caucus. But while the federal change is drawing bipartisan backing for new laws in Tennessee, Lt. Gov. Randy McNally said he has “no interest” in changing how the state schedules marijuana. McNally, an Oak Ridge Republican, pointed out that Schedule III drugs remain tightly regulated and can be dispensed only by a pharmacist at a doctor’s direction, usually for short-term use. He added that recommended dosages would have to be established and new rules set up for dispensing medical cannabis. “While the federal change does allow easier study and testing of the drug, I have no interest in changing how we schedule marijuana in Tennessee. In my mind it remains a dangerous drug with little demonstrated medicinal efficacy,” said McNally, who is also speaker of the Senate. Tennessee lawmakers who sought to pass medical marijuana laws previously ran into opposition from McNally, who said he couldn’t support a change because of the federal government’s Schedule I classification of cannabis. This story was first published by Tennessee Lookout. The post Bipartisan Tennessee Lawmakers Push For State-Level Marijuana Reform Following Trump’s Federal Rescheduling Move appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Many thanks with regard to supplying current improvements concerning the issue, We anticipate study much more. https://www.aerogaga.com/

Thanks for your time designed for advertisment a great very good guide! I noticed your internet-site ideal for a must have. It has splendid and even effective content articles. Compete the best get the job done! https://www.aerogaga.com/

Frequent goes to here i will discuss the obvious way to appreciate it on your attempt, which often is why Now i am viewing the internet site day-to-day, in search of completely new, useful facts. Quite a few, many thanks! 오피사이트 Certainly great, remarkable, fact-filled tips these. Ones own content articles Be required to fail, thinking that obviously is true these on top of that. One normally generate an intriguing browse. On earth do you enlighten So i'm shocked?: )#) Compete the great articles and reviews. mawarcuan88 daftar I had most recently initiated a fabulous web page, the details you will provide you with here comes with really helped others really. Regards just for all of the effort & succeed. KAVIAR88 Helpful — I valued the transparency on player complaint resolution timelines. Quick, fair resolution processes prevent toxic situations from escalating. Real votes showed which teams are responsive. 오피사이트 Positive site, where did u come up with the information on this posting? I'm pleased I discovered it though, ill be checking back soon to find out what additional posts you include. situs slot

Steal Brainrot offers nonstop action with meme humor, base raids, and deep progression systems. Can you survive the chaos? Play today!

It's so inspiring to read about Dutch Valley Farms and their commitment to sustainable practices and quality cannabis! It’s heartwarming to see a family-owned farm making such a positive impact not only in the cannabis community but also for families dealing with similar challenges. Their approach to farming and research is truly admirable. By the way, if you enjoy games with a bit of thrill, you might want to check out Snow Rider 3D for some fun escapism!

Ohio activists are launching a campaign to hit the brakes on a bill the governor recently signed to scale back the state’s voter-approved marijuana law and ban the sale of consumable hemp products outside of licensed cannabis dispensaries. Ohioans for Cannabis Choice said on Friday that they’d be collecting signatures for the statewide referendum, which would pause the implementation of SB 56 until voters got a say at the next regular or general election. Gov. Mike DeWine (R) has been adamant about cracking down on the unregulated intoxicating hemp market, but the legislation he signed would do more than restrict the sale of cannabinoid products to dispensaries. It would also recriminalize certain marijuana activity that was legalized under the ballot initiative voters approved in 2023, and it’d additionally remove anti-discrimination protections for cannabis consumers that were enacted under that law. The governor also used his line-item veto powers to cancel a section of the bill that would have delayed the implementation of the ban on hemp beverages. Advocates and stakeholders strongly protested the now-enacted legislation, arguing that it undermines the will of voters and would effectively eradicate the state’s hemp industry, as there are low expectations that adults will opt for hemp-based products over marijuana when they visit a dispensary. The pushback inspired the newly filed referendum—but the path to successfully blocking the law is narrow. Ohioans for Cannabis Choice must first collect an initial batch of 1,000 valid signatures, which would need to be certified by the secretary of state’s office, and then submit a total of about 250,000 signatures to make the ballot. “SB 56 forcefully defies the will of the voters of Ohio, who spoke clearly on this issue, and denies the people of Ohio the freedom to use these products for their personal use,” Dennis Willard, spokesperson for the campaign, said. “We are launching a referendum campaign to go directly to the voters,” he said. “We believe voters will say no to government overreach, no to closing 6,000 small businesses and pink-slipping thousands of workers across the state, and no to once again recriminalizing hemp and marijuana.” If activists reach the signature threshold by the deadline three months from now, which coincides with the same day the restrictive law is to take effect, SB 56 would not be implemented until voters got a chance to decide on the issue at the ballot. Advocates have flagged a series of concerns with the law, pointing out, for example, that it would eliminate language in statute providing anti-discrimination protections for people who lawfully use cannabis. That includes protections meant to prevent adverse actions in the context of child custody rights, the ability to qualify for organ transplants and professional licensing. It would also recriminalize possessing marijuana from any source that isn’t a state-licensed dispensary in Ohio or from a legal homegrow. As such, people could be charged with a crime for carrying cannabis they bought at a legal retailer in neighboring Michigan. Additionally, it would ban smoking cannabis at outdoor public locations such as bar patios—and it would allow landlords to prohibit vaping marijuana at rented homes. Violating that latter policy, even if it involves vaping in a person’s own backyard at a rental home, would constitute a misdemeanor offense. The legislation would also replace what had been a proposed regulatory framework for intoxicating hemp that the House had approved with a broad prohibition on sales outside marijuana dispensaries following a recent federal move to recriminalize such products. Under the law, hemp items with more than 0.4 mg of total THC per container, or those containing synthetic cannabinoids, could no longer be sold outside of a licensed marijuana dispensary setting. That would align with a recently enacted federal hemp law included in an appropriations package signed by President Donald Trump. The federal law imposing a ban on most consumable hemp products has a one-year implementation window, however, and it appears the Ohio legislation would take effect sooner. As passed by the legislature, a temporary regulatory program for hemp beverages would have stayed in place in Ohio until December 31, 2026, but that provision was vetoed by the governor. The law also includes language stipulating that, if the federal government moves to legalize hemp with higher THC content, it’s the intent of the Ohio legislature to review that policy change and consider potential state-level reforms to regulate such products. The bill signing came months after DeWine issued emergency rules prohibiting the sale of intoxicating hemp products for 90 days, with instructions to the legislature to consider permanent regulations. A county judge has enjoined the state from enforcing that policy in response to a legal challenge. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, in September, the Ohio Department of Cannabis Control (DCC) filed proposed rules to build upon the state’s marijuana legalization law, laying out plans to update regulations on labeling and packaging requirements. The proposal came weeks after Ohio medical and adult-use marijuana sales officially crossed $3 billion, data from the state Department of Commerce (DOC) shows. The state sold about $703 million in recreational cannabis in the law’s first year of implementation, according to DCC data. In March, a survey of 38 municipalities by the Ohio State University’s (OSU) Moritz College of Law found that local leaders were “unequivocally opposed” to earlier proposals that would have stripped the planned funding. Meanwhile in Ohio, adults as of June are able to buy more than double the amount of marijuana than they were under previous limits, with state officials determining that the market can sustainably supply both medical cannabis patients and adult consumers. The governor in March separately announced his desire to reallocate marijuana tax revenue to support police training, local jails and behavioral health services. He said funding police training was a top priority, even if that wasn’t included in what voters passed in 2023. The post Ohio Activists Plan Referendum To Block New Law Rolling Back Marijuana Rights And Restricting Hemp Sales appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A top Trump administration health official said last week that his agency will soon launch a novel program to have Medicare cover the costs of CBD for certain patients. But while the administration has not yet released specific details about the initiative’s rollout, one cannabis company that says it’s partnering with the government on the effort has since shed some light on what to expect. At a White House event last week, President Donald Trump signed an executive order directing the attorney general to complete the process of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). But another major reform was also announced: A pilot program enabling eligible patients to access hemp-derived cannabidiol that’d be covered under federal health insurance plans, projected to launch by April. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services (CMS), spoke about the initiative at the signing ceremony, crediting Trump and U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. for “pushing for change” and “relentlessly” pursuing an agenda rooted in a “deep passion for research.” Oz said Trump called him “frequently” to discuss the potential benefits of CBD after hearing from friends who “got relief” from the cannabinoid product, and per his direction, CMS has created “a new model” and taken “additional actions to give seniors access to cannabinoids.” “These are CBDs—they’re not addictive—which many are already using to manage pain,” he said. “There’s some clinical evidence that showing that CBDs provide relief from common conditions that affect Americans, including cancer symptoms and chronic pain and a slew of other problems that affect disproportionately seniors and our veterans.” There are relatively few specific details about the new model, however, and the CMS website hasn’t yet posted information about the rollout or who would specifically qualify. That said, Oz explained that the policy change will “allow millions of Americans on Medicare to become eligible to receive CBD as early as April of next year—and at no charge if their doctors recommend them.” One outstanding question concerns coverage eligibility. As described, it would affect those 65 and older who qualify for Medicare, but the specific qualifying conditions weren’t detailed. There was repeated mention of chronic pain, specifically related to cancer, but it’s possible the CBD eligibility criteria includes additional conditions. Marijuana Moment reached out to CMS for additional clarity about the plan, but representatives did not respond by the time of publication. At the Oval Office event, Oz said “sometimes these decisions are difficult,” and that while other presidents have “whiffed on this issue” because it’s “tough,” this administration is “passionate about making it clear that this patchwork that we’re working within now, the laws and regulations, they’re leaving patients and doctors without adequate guidance on the safeguards of how to use these products, even though they’re still being used.” The administrator added that Medicare Advantage insurers CMS has contacted are “also agreeing to consider CBD to be used for the 34 million Americans that they cover.” “If you can hear my voice and you’re over 65, you should pay attention to this executive order, because it’s going to touch your life,” Oz said. “Again, this all becomes active after the first quarter of next year. These CBD products must first meet local and state quality and safety standards. They must come from legitimate sources. They must abide by other regulations of those states with these boxes checked.” He said patients can be reimbursed for up to $500 worth of hemp-derived cannabinoid products per year, and CMS will be collecting data on the patient outcomes and making the data publicly available to analyze. “If it shows promise, we will expand access to these products to even more conditions amongst Medicare [and] Medicaid beneficiaries,” he said. Oz also gave kudos to Howard Kessler, founder of The Commonwealth Project, which produced a video about the benefits of cannabidiol for seniors that Trump shared on Truth Social earlier this year and who apparently has pressed the president to enact reform to expand cannabis access. One company that says it will be participating in the CBD pilot program is Charlotte’s Web, which has long advocated for reform and focused on the therapeutic potential of cannabinoids for people with severe epilepsy. CEO Bill Morachnick said in a press release that the business is “proud” to “bring trusted CBD options to underserved seniors battling cancer” through the initiative. “Charlotte’s Web was founded to help Charlotte Figi, whose medically challenging life became a CBD success story,” he said. “Her journey inspired research, opened doors to access, and changed perceptions about the therapeutic benefits of CBD around the globe.” “The Company made a promise to Charlotte, her mother Paige, and the millions who followed her: to set the standard for the entire industry by leading with quality, consistency, and science,” he said. “As the CBD market leader and a trusted partner throughout the country among healthcare practitioners, this initiative marks a historic step forward, uniquely positioning Charlotte’s Web to expand access to safe, non-intoxicating hemp CBD products through existing pathways.” “This initiative represents a blueprint for patient-centered CBD healthcare—one that advances alongside our medical channel expansion and deepening clinical research. The potential of the hemp plant is still being furthered, and studies like the Phase 2 FDA clinical trials investigating hemp-based therapies for autism spectrum disorder at our affiliated company, DeFloria, are critical to making its therapeutic promise even more accessible for health insurance-covered care. Our work through this program and our ongoing research demonstrate how rigorous science and compassionate care can converge to serve patients who need it most.” “This pilot program would inform potential expansion into other patient populations to use CBD to support sleep, anxiety, pain, and general wellness as identified in the Federal Register,” the company said, referencing a recent notice from CMS about its existing plans to authorize health insurance coverage for CBD under certain Medicare programs. While CMS implemented an earlier 2026 final rule in April specifically stipulating that marijuana, as well as CBD that can be derived from federally legal hemp, are ineligible for coverage under its Medicare Advantage program and other services, the agency has since revised that policy. The Commonwealth Project estimates that 8,000-12,000 patients will participate in the program, with projections of up to $64 billion in “potential annual savings through improved symptom management and reduced reliance on certain high-cost interventions,” according to information in a press pitch on behalf of Charlotte’s Web. While Oz said April 2026 is when eligible patients will be able to take advantage of the policy change, the hemp stakeholders’ press pitch said the pilot program itself is set to launch in January. Marcel Bonn-Miller, chief scientific officer at Charlotte’s Web, said “scientific rigor underpins every aspect of this program.” “With more than a decade of consumer use and extensive safety studies, Charlotte’s Web integrates real-world evidence, patient-reported outcomes, and clinical insights into its R&D process to ensure products are safe and effective,” he said. Meanwhile, following the White House announcement last week, Oz spoke with NewsNation about the policy change, responding to a question about how the broader marijuana rescheduling decision squares with the Trump administration’s aggressive efforts to stymie the flow of other illicit drugs, particularly fentanyl. “We think they fit hand in hand,” he said. “This is really about researching—specifically CBD, which is hemp-derived endocannabinoids [sic]—are actually worthy of Americans using them,” he said. “It’s hard to do some of this work, especially with medical marijuana. And this is not about legalization of marijuana.” “There is no legalization language at all,” he added. “It’s about rescheduling this class of product so that it can be researched more readily.” The idea that marijuana has no medical value, as its currently defined as a Schedule I drug, is “just patently wrong for marijuana,” he said, noting that the Food and Drug Administration (FDA) has approved certain cannabis-based drugs for conditions such as epilepsy “that work quite nicely.” “That belief that it should be Schedule I is just an incorrect place to put it,” he said. “Schedule III seemed to make sense to the president. He argued that it allows us to do the research more readily.” “We’re finding a way to allow Medicare beneficiaries to get access to some of these products. And so, within Medicare, we have the ability, for the first time ever—and we delivered on this promise to the president today—to allow doctors to recommend hemp-derived CBD for patients who have cancer, for example, and have a lot of pain from that.” The administrator said surveys show a majority of seniors who take CBD for pain management find it beneficial, and the White House wants to “make it easier for patients to access this” and allow them to access the cannabinoid at “no charge” through the federal health insurance program. “If it works well, we’re going to get a lot of data—and we’ll know a ton more about whether this truly makes a difference for the American people,” Oz said. “But again, I want to emphasize this: I don’t like marijuana smell walking down the streets. The president doesn’t either.” Trump and Kennedy “don’t drink, so they definitely don’t smoke marijuana. So this is not about legalizing these products,” he said. In recent years, Dr. Oz has encouraged audiences to be open to therapeutic cannabis and advocated for sweeping policy changes around the drug. “We ought to completely change our policy on marijuana. It absolutely works,” he said in a 2020 interview, calling cannabis “one of the most underused tools in America.” Last year, he wrote in a syndicated health column that there’s evidence cannabinoids can curb seizures, alleviate nausea associated with cancer treatment and potentially help manage pain—especially in older people. Oz also said in 2020 that he believes that, particularly for seniors, marijuana for pain represents a “safer solution than, for example, narcotics in many cases.” The post Federal Health Programs Will Cover Up To $500 Worth Of CBD For Certain Patients By April, Trump Official Dr. Oz Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Awesome and interesting article. Great things you've always shared with us. Thanks. Just continue composing this kind of post. <a href="https://www.awfenceworks.com/blog/">situs togel</a>

“Law enforcement officers, first responders and veterans carry real trauma, and too many run out of options.” By Jack Gorsline, Psychedelic State(s) of America In a historic move on Friday, the Massachusetts Joint Committee on Public Health voted to advance two pivotal pieces of legislation regarding psilocybin, marking a significant shift in the state’s approach to psychedelic medicine. Specifically, lawmakers voted to advance H.2532, a bill establishing a framework for psilocybin therapy, alongside a new draft of H.2506, a measure designed to legalize the use of psilocybin specifically for veterans, law enforcement officers and qualifying patients. The vote represents the first time a committee in the Massachusetts legislature has approved psilocybin legalization, setting a new precedent for drug policy reform in the commonwealth. The committee’s decision was bipartisan and nearly unanimous. According to committee staff, 10 of the 11 members voted in favor of the proposal, with only a single lawmaker abstaining. Notably, the “yes” votes included Air Force veterans Rep. Shirley Arriaga (D) and Rep. Justin Thurber (R), underscoring the legislation’s strong appeal among those familiar with the mental health challenges facing service members. A Patient-First Approach The advancement of these bills comes in the wake of the scandal-plagued, ultimately-failed 2024 psychedelics ballot question, which sought to legalize widespread recreational use and distribution. While that measure was rejected by voters, the legislation advanced Friday takes a markedly different, “patient-focused” approach. H.2506 was primarily authored by Graham Moore of the advocacy group Mass Healing, in collaboration with Rep. Steven Owens (D). The bill was drafted in consultation with a psychiatrist from the Massachusetts Psychiatric Society (MPS) and two pharmacists, ensuring the language prioritized medical safety and targeted relief for specific vulnerable populations rather than broad open access. “Whatever the merits of taking psilocybin ‘for fun,’ it is a distinct issue from whether individuals with cancer or severe depression should be dragged through the courts for seeking relief,” said Moore, reflecting on the legislative victory. “The ballot question last year was a politically irresponsible experiment to decriminalize recreational use on the backs of patients like me, who campaigned for it for lack of a better alternative. But unlike the out-of-state architects of the failed ballot question, patients in Massachusetts cannot afford to stop fighting.” Historic Momentum for Mental Health The Joint Committee on Public Health’s vote is the latest in a series of historic developments for psychedelic policy in Massachusetts this year. In January, Mass Healing’s leadership worked with state lawmakers to file a record number of psychedelic proposals. To date, four of the 11 bills filed have been reported favorably out of committee, with none tabled—a high success rate for such a novel policy area. In July, the Massachusetts Psychiatric Society formally endorsed three psilocybin decriminalization bills. This endorsement marked the first time any branch of the American Psychiatric Association (APA) nationwide has formally backed such legislation, signaling a shift in the medical community’s willingness to explore psychedelic adjunctive therapies. Additionally, in August, the Joint Committee on Mental Health, Substance Use and Recovery approved a psychedelic therapy bill, further paving the way for the Public Health Committee’s recent action. Voices from the Frontlines The push for H.2506 has been heavily driven by those on the front lines of trauma: veterans and first responders. Mass Healing volunteers spent months organizing support, culminating in an outpouring of written testimony from residents, psychiatrists and public safety officials. Lt. Sarko Gergerian, a police lieutenant and member of the Law Enforcement Action Partnership (LEAP), emphasized the practical benefits of the legislation for public safety and mental health. “I am so grateful to the Joint Committee on Public Health for their wisdom and compassion in advancing a psilocybin therapy pilot bill in combination with long overdue protections for vulnerable patients,” Gergerian said. “Law enforcement officers, first responders and veterans carry real trauma, and too many run out of options. This evidence-based proposal honors those who serve, advances science and frees up police resources for where they are needed most.” Gergerian, who holds master’s degrees in counseling and criminal justice, also thanked Committee Chair Marjorie Decker for her leadership. “With Chair Decker’s recommendation, the public health committee has sent a resounding message: healing should not be a crime,” he added. Broad Coalition of Support A diverse coalition spanning veterans’ rights, healthcare and criminal justice reform has rallied behind the legislation, lending significant political weight to the proposal. Among the most notable endorsements is from Disabled American Veterans (DAV), which represents more than 60,000 disabled veterans across the commonwealth. Their support is bolstered by advocacy groups focused on the suicide epidemic among service members, including the Massachusetts-based Minus 22 Foundation and the No Fallen Heroes Foundation, whose founder, U.S. military veteran Matthew “Whiz” Buckley, recently highlighted the potential of psychedelic therapies during an appearances at Harvard University’s Petrie-Flom Center. Beyond the veteran community, the bill has secured critical backing from law enforcement and patient advocacy groups, challenging traditional narratives around drug policy. The Law Enforcement Action Partnership (LEAP), a national nonprofit of police, prosecutors and judges, has formally endorsed the measure, emphasizing the need to support officers and first responders carrying trauma. Additionally, Clusterbusters, a national organization representing patients with cluster headaches, has thrown its support behind the bill, citing the responsiveness of their notoriously treatment-resistant condition to psilocybin in early clinical reports. National Significance Friday’s vote distinguishes Massachusetts as a national leader in targeted drug policy reform. While other states like Oregon and Colorado have moved toward broader legalization or regulated access models, the Massachusetts legislature is the first to have a committee approve a strictly patient-focused legalization bill. A similar attempt in the Michigan legislature failed to advance out of committee earlier this session. Observers suggest that the Massachusetts model—pairing clinical research frameworks (H.2532) with immediate legalization for those with medical needs (H.2506)—could serve as a blueprint for other states where voters or lawmakers are wary of full recreational legalization but sympathetic to the mental health crisis. Looking Ahead The bills now move to the next stage of the legislative process, where they must pass through further committees and eventually floor votes in both the House and Senate. Advocates remain optimistic. Mass Healing’s Moore and Morey have expressed hope that the continued support of legislative thought leaders—including Rep. Marjorie Decker (D), Rep. Jim O’Day (D), Sen. Cindy Friedman (D), Rep. Lindsay Sabadosa (D) and Rep. Steven Owens (D)—will steer the bills to final passage. For the veterans and patients waiting for legal clarity, the committee’s vote is more than a procedural step; it is a validation of their struggle. By stripping away the threat of prosecution for those seeking healing, Massachusetts lawmakers are acknowledging that for many, psilocybin is not a party drug, but a lifeline. This article was produced by Psychedelic State(s) of America – a nonprofit-sponsored news organization dedicated to rigorous independent psychedelic journalism. Subscribe to PSA online and Follow PSA on Instagram, LinkedIn, Twitter/X, Facebook. Learn more about PSA and donate to the PSA Media Fund here. Image courtesy of CostaPPR. The post Massachusetts Lawmakers Vote To Legalize Psilocybin And Establish Framework For Therapeutic Access appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Wonderful posting, Thanks a ton to get spreading The following awareness. Wonderfully authored posting, doubts all of blog owners available precisely the same a higher standard subject material just like you, online has got to be improved site. I highly recommend you stay the best! 99dewa pkv

Florida lawmakers have filed new bills for the 2026 session that would reduce medical cannabis patient registration fees for military veterans and clarify that smoking or vaping marijuana in public places is prohibited. Sen. Keith Truenow’s (R) proposal would make it so that veterans would only need to pay a $15 state fee to receive, renew or replace a medical marijuana patient ID card. That’s a significant reduction from the standard rate of $75. In order to prove eligibility under the bill, the patient would need to provide a Certificate of Release or Discharge from Active Duty form from the military, a Department of Veterans Affairs identification card or a Florida driver license bearing the veteran designation. Rep. Susan Valdes (R) is sponsoring a companion measure in the House of Representatives. The other new bill, from Sen. Joe Gruters (R), would ban smoking or vaping cannabis in public places. The legislation defines a public place as “a place to which the public has access, including, but not limited to, streets; sidewalks; highways; public parks; public beaches; and the common areas, both inside and outside, of schools, hospitals, government buildings, apartment buildings, office buildings, lodging establishments, restaurants, transportation facilities, and retail shops.” The measure from Gruters, who is also chairman of the Republican National Committee, would also specify that marijuana cannot be smoked or vaped in customs smoking rooms at airports. Rep. Alex Andrade (R) filed a similar bill to ban public cannabis smoking last month. The new proposals are among a growing list of cannabis legislation that lawmakers are introducing for consideration next year. Earlier this month, Rep. Bill Partington (R) introduced a bill to expand the state’s medical marijuana program in a number of ways, including by allowing doctors to recommend cannabis to any patient who has a condition for which they have been prescribed opioids. It would also make it so medical marijuana registrations could last up to two years instead of the current 30 weeks, and it’d waive patient registration fees for honorably discharged military veterans. Under the proposal, doctors would additionally be able to recommend medical cannabis via telehealth without a physical examination—expanding a current policy that allows renewals, but not initial certifications, to be conducted remotely. There are also reciprocity provisions built into the measure, requiring regulators to create a process to issue medical cannabis registration cards to “nonresidents who are actively enrolled in the medical cannabis program of another jurisdiction recognized by the department within 1 business day.” It specifies that “a visiting qualified patient may engage in all conduct authorized for a qualified patient.” Another section of the bill stipulates that doctors could certify patients to receive up to 10 70-day supply limits of smokable medical marijuana, rather than three. They could also issue up to 20 35-day supply limits instead of the current six. That measure was filed just days after a Florida Democratic senator introduced legislation for the 2026 session that would legalize home cultivation of marijuana for registered medical cannabis patients in the state. The proposal would permit qualified patients who are at least 21 years old to cultivate up to six flowering plants for personal, therapeutic use. Those patients could also buy seeds and clones from licensed dispensaries. The legislative proposals come as the state’s attorney general is asking the Florida Supreme Court to review the constitutionality of a marijuana legalization initiative that an industry-funded campaign is seeking to place on the 2026 ballot. A similar measure on the 2024 ballot received majority voter support but did not reach the 60 percent threshold required for enactment under state law. In March, meanwhile, two Democratic members of Congress representing Florida asked the federal government to investigate what they described as “potentially unlawful diversion” of millions in state Medicaid funds via a group with ties to Gov. Ron DeSantis (R). The money was used to fight against the 2024 initiative. The lawmakers’ letter followed allegations that a $10 million donation from a state legal settlement was improperly made to the Hope Florida Foundation, which later sent the money to two political nonprofits, which in turn sent $8.5 million to a campaign opposing Amendment 3. The governor said in February that the newest marijuana legalization measure is in “big time trouble” with the state Supreme Court, predicting it will be blocked from going before voters next year. “There’s a lot of different perspectives on on marijuana,” DeSantis said. “It should not be in our Constitution. If you feel strongly about it, you have elections for the legislature. Go back candidates that you believe will be able to deliver what your vision is on that.” “But when you put these things in the Constitution—and I think, I mean, the way they wrote, there’s all kinds of things going on in here. I think it’s going to have big time trouble getting through the Florida Supreme Court,” he said. The latest initiative was filed with the secretary of state’s office just months after the initial version failed during the November 2024 election—despite an endorsement from President Donald Trump. Smart & Safe Florida is hoping the revised version will succeed in 2026. The campaign—which in the last election cycle received tens of millions of dollars from cannabis industry stakeholders, principally the multi-state operator Trulieve—incorporated certain changes into the new version that seem responsive to criticism opponents raised during the 2024 push. For example, it now specifically states that the “smoking and vaping of marijuana in any public place is prohibited.”Another section asserts that the legislature would need to approve rules dealing with the “regulation of the time, place, and manner of the public consumption of marijuana.” Last year, the governor accurately predicted that the 2024 cannabis measure from the campaign would survive a legal challenge from the state attorney general. It’s not entirely clear why he feels this version would face a different outcome. While there’s uncertainty around how the state’s highest court will navigate the measure, a poll released in February showed overwhelming bipartisan voter support for the reform—with 67 percent of Florida voters backing legalization, including 82 percent of Democrats, 66 percent of independents and 55 percent of Republicans. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In the background, a recent poll from a Trump-affiliated research firm found that nearly 9 in 10 Florida voters say they should have the right to decide to legalize marijuana in the state. Separately, Florida medical marijuana officials are actively revoking the registrations of patients and caregivers with drug-related criminal records. The policy is part of broad budget legislation signed into law earlier this year by DeSantis. The provisions in question direct the state Department of Health (DOH) to cancel registrations of medical marijuana patients and caregivers if they’re convicted of—or plead guilty or no contest to—criminal drug charges. Photo courtesy of Chris Wallis // Side Pocket Images. The post Florida Bills Would Reduce Medical Marijuana Fees For Military Veterans And Ban Public Smoking appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Inside Trump’s marijuana meeting; State AGs tell SCOTUS: Keep cannabis user gun ban; Fed study: Teen marijuana use “stable”; Cannabis & holidays Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… By starting a $10 per month pledge on Patreon—or about 45 cents per issue of this newsletter—you can help us rely less on ads to cover our expenses, hire more journalists and bring you even more marijuana news. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Sen. John Hickenlooper (D-CO) filed a marijuana bill that would direct the attorney general to form a commission to prepare for federal legalization by recommending cannabis regulations modeled after those currently in place for alcohol. Scotts Miracle-Gro CEO Jim Hagedorn revealed details about an “insane” marijuana rescheduling meeting in the Oval Office at which he said President Donald Trump described a compromise to put cannabis in Schedule II as a “half-assed” alternative to Schedule III. Attorneys general from 19 states and Washington, D.C. filed a brief asking the U.S. Supreme Court to uphold the federal law restricting marijuana consumers’ gun rights—saying that lower court rulings against the ban are “flawed in multiple respects.” The latest results of the federally funded Monitoring the Future survey show that teen marijuana use “remained stable” last year—even as more states continue to legalize cannabis—and that it is lower now than before states started enacting the reform. State marijuana regulators are offering guidance about how to legally gift marijuana for the holidays and stay safe while celebrating. / FEDERAL The Drug Enforcement Administration promoted a podcast about the role of athletics in supporting drug prevention. Rep. Eleanor Holmes Norton (D-DC) inserted comments into the Congressional Record about her bill to protect people from being evicted from public housing for marijuana use. Rep. Sydney Kamlager-Dove (D-CA) tweeted, “Transferring cannabis from Schedule I to Schedule III is a meaningful step toward decriminalization. Last year, I urged the Biden Administration to reclassify marijuana, and I was encouraged when they began the rescheduling process. While I welcome this administration’s continuation of that work, I will continue to closely monitor the rule-making process and assess the rescheduling’s impact on expungements, advocate for protections for small businesses against industry consolidation, and ensure this progress is used to reinvest in our local communities—especially those most harmed by the War on Drugs.” Rep. Jared Huffman (D-CA) filed a bill that includes provisions to rehabilitate lands damaged by illegal marijuana growing operations. Rep. Tom McClintock (R-CA) tweeted, “Pot is a bad idea. So is criminalizing it. In a free society, grownups should make these decisions for themselves. Kudos to Trump for his EO today. Congress should finish the job.” / STATES New York Gov. Kathy Hochul (D) signed kratom regulation legislation. Nevada Gov. Joe Lombardo (R) announced a new chair of the Cannabis Compliance Board. South Dakota’s attorney general said rescheduling marijuana can boost research. New Jersey lawmakers sent Gov. Phil Murphy (D) a bill to ban intoxicating hemp product sales. Wisconsin’s Senate president said her chamber is “closer than ever” to voting on medical cannabis legislation, but said the chances of the Assembly advancing the issue are “slim.” A Delaware representative filed a bill to make consumption of marijuana in public places or in a moving vehicle a civil violation rather than a misdemeanor. Rhode Island regulators filed proposed changes to marijuana rules. Michigan regulators published a monthly report on disciplinary actions taken against marijuana businesses. California regulators said President Donald Trump’s marijuana rescheduling order is “a significant step toward grounding federal cannabis laws in evidence rather than stigma and fear.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Jersey’s minister for health and social services is asking lawmakers to choose between three marijuana reform options ahead of a debate scheduled for February 3. / SCIENCE & HEALTH A study found that “CBD reduced prostate cancer cell viability and proliferation, with the therapeutic potential to synergise with targeted therapies.” A study of dental extraction patients found that “higher-concentration CBD (37 mg/mL) may provide analgesia comparable to standard non-opioid therapy.” A study found that “psilocybin reduces comorbid chronic pain and depression in mice.” / ADVOCACY, OPINION & ANALYSIS The chair of the Idaho Republican Party said patients should have a “right to try” medical cannabis if their doctor sees a benefit. The American Civil Liberties Union is calling on Congress to build on President Donald Trump’s marijuana rescheduling move by passing legalization legislation. / BUSINESS Vireo Growth Inc. is acquiring Eaze Inc. NJ Leaf workers in North Brunswick, New Jersey voted to unionize. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Federal cannabis legalization commission proposed under Senate bill (Newsletter: December 24, 2025) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Helpful — I valued the transparency on player complaint resolution timelines. Quick, fair resolution processes prevent toxic situations from escalating. Real votes showed which teams are responsive. 오피가이드

However, many Lucknow Call Girls providers need to be more reliable and professional, as they often deceive their clients with misleading photos and information. This is the reason the call girl sector is a topic of intense discussion in dating services.

Finding out that groups like Women Grow and Tokativity are actively using social media and meetups to change perceptions in the cannabis industry-it’s inspiring! Imagine reading this while waiting for my morning coffee, it’s a boost of motivation! @Banana AI

115. 5-MeO-DMT Experience Explained A grounded conversation on the 5-MeO-DMT experience—how it affects the nervous system, how it differs from DMT, and why safety and integration matter. Episode Summary What is 5-MeO-DMT, and why do people describe it so differently from other psychedelics? In this episode, April Pride sits down with licensed clinicians and facilitators Roger and Dustin to explore the 5-MeO-DMT experience through both lived experience and emerging neuroscience. Often referred to as the God molecule psychedelic, 5-MeO-DMT is widely described as a non-visual psychedelic experience—one that quiets the nervous system rather than amplifying imagery, stories, or symbols. Together, they break down 5-MeO-DMT vs DMT, explain how this compound interacts with serotonin receptors in the brain, and discuss why many people report profound ego dissolution, nervous system regulation, and long-term shifts in how they experience safety and connection. This episode also centers women and psychedelics, examining why women—particularly those who have spent years in control, caretaking, or emotional labor—may feel especially drawn to this form of surrender-based medicine. If you’re seeking grounded insight into psychedelic harm reduction, integration after 5-MeO-DMT, and what makes this medicine fundamentally different from other psychedelic experiences, this conversation is an essential listen. Key Takeaways The 5-MeO-DMT experience is often felt rather than seen, with little to no visuals or narrative content Unlike classic psychedelics, 5-MeO-DMT is widely described as a non-visual psychedelic experience Understanding 5-MeO-DMT vs DMT is critical—many vape pens labeled “DMT” contain N-N-DMT, not 5-MeO-DMT 5-MeO-DMT strongly activates both 5-HT2A and 5-HT1A serotonin receptors, impacting cognition and nervous system regulation The medicine often quiets the nervous system rather than stimulating imagery or meaning-making Synthetic 5-MeO-DMT allows for more precise dosing and supports harm reduction by protecting the Sonoran Desert toad Women may experience particular resonance due to lifelong patterns of regulation, control, and emotional labor Psychedelic integration after 5-MeO-DMT is essential; the effects unfold over time, not just during the session Screening, contraindications, and aftercare are non-negotiable components of responsible psychedelic use Timestamps [00:00] What people mean when they describe the God molecule psychedelic [02:10] How Roger and Dustin came to work with 5-MeO-DMT [03:36] Why this is a non-visual psychedelic experience [04:22] Synthetic vs toad-derived 5-MeO-DMT and harm reduction [06:57] Why some therapeutic “stuckness” responds differently to 5-MeO-DMT [08:28] Serotonin receptors and psychedelics: the double-door explanation [10:00] Nervous system regulation and surrender, especially for women [11:14] Gamma brainwaves, endogenous release, and embodied remembering [13:41] April’s experience with DMT vapes and common confusion [16:19] Clear distinctions between 5-MeO-DMT vs DMT [18:30] Health risks, medications, and serotonin syndrome [20:30] Ketamine, DMT, and the limits of comparison [22:53] Why women and psychedelics intersect uniquely here [23:21] Integration, meaning-making, and what comes after the experience Guests Roger & DustinLicensed clinicians and facilitators at Sky Mountain Retreats, specializing in carefully screened, harm-reduction-focused 5-MeO-DMT experiences with an emphasis on preparation, precision dosing, and long-term integration. Additional Resources SetSet Psychedelic Cards Women in the Wild application Learn more about this episode: https://aprilpride.substack.com/p/5-meo-dmt-experience-nervous-system-safety Hosted by April Pride Subscribe for April’s newsletter on Substack at https://aprilpride.substack.com/subscribe or at getsetset.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow on IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset Get full access to SetSet with April Pride at aprilpride.substack.com/subscribeCatch the full episode here

Another holiday season has arrived—and, with it, another round of public service announcements from regulators in states that have legalized marijuana that are aimed at advising people about how to comply with the law and stay safe amid the merriment. This has become something of a trend over recent years, with states increasingly using the annual occasion to promote messaging focused on education over stigma to help cannabis consumers better understand the laws—particularly around impaired driving—while also offering advice to prevent overindulgence. This year, cannabis regulators in New Jersey and Virginia have put out holiday-themed social media and blog posts about safe consumption practices. “The holidays are a time for food, fun, laughter, and connecting with the people who make life sweeter,” the New Jersey Cannabis Regulatory Commission (NJ-CRC) said. “And as more adults in New Jersey choose to enjoy, or gift legal cannabis during the season, the NJ-CRC has launched its second safe-use campaign, S.M.A.R.T., to help keep celebrations (relatively) stress-free.” The acronym stands for “Safe, Mindful, Aware, Responsible and Thoughtful.” “S.M.A.R.T. is an easy way to remember the basics of responsible cannabis use, especially when travel is constant, roads are chaotic, homes are busy, and curious little ones are wandering,” the officials said. “Whether you’re a host, a guest, a first-time weed shopper, someone who already knows their way around a dispensary, or can roll up with one hand, being S.M.A.R.T. helps everyone to relax and enjoy the season,” the state blog post says. “Be Safe. Be Mindful. Be Aware. Be Responsible. Be Thoughtful. Be S.M.A.R.T. this holiday season.” Wishing you a holiday season filled with love, happiness, and good vibes. If cannabis is a part of your celebration, keep it away from kids, use in moderation, and don’t drive high. pic.twitter.com/iTRWhB3nAG — New Jersey Cannabis Regulatory Commission (@NewJerseyCRC) December 22, 2025 On X, NJ-CRC emphasized that people who use marijuana in compliance with state law should not drive after using cannabis, ensure that marijuana products are kept away from children and practice moderation. Virginia’s Cannabis Control Authority (CCA), meanwhile, shared a post stressing the importance of understanding the state’s unique marijuana law, particularly as it concerns “gifting.” Planning to give the gift of green this year? (wink*wink*) Before you do, make sure you’re doing it legally. We break down legal adult exchanges of cannabis: https://t.co/ELOe9YUjNV pic.twitter.com/VCGNmDF91f — Virginia Cannabis Control Authority (@Virginia_CCA) December 4, 2025 Possession, as well as non-commercial gifting, of cannabis is permitted under the current law in Virginia. But there are certain policy parameters to keep in mind as lawmakers look to 2026 to establish a retail market under an incoming pro-reform governor. “While ‘adult sharing’ of cannabis between people 21 years and older is legal in Virginia, this term only applies to specific situations. Other exchanges may be illegal and can carry penalties. Common illegal exchanges are known as ‘gifting schemes,'” the CCA’s guidance says. “‘Gifting’ cannabis to someone as part of the sale of another good or service, like a sticker or seminar” is not legal, it says. Several other states—from California to New York—have also historically publicized public education campaigns around the holidays in recent years. About one in three Americans say their holiday “pregame” routine involves using marijuana, according to a new survey. Mainstream media outlets this past November also picked up on a trend that’s long been practiced within the cannabis community: the “cousin walk,” a Thanksgiving pre-game (and usually pre-dinner) tradition for some where the typically younger adults at a gathering will sneak away for a cannabis break before the feast begins. The post State Marijuana Regulators Share Tips On How To Stay Safe And Legal Around The Holidays appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net